Affimed N.V. (0HL9.L)

4,7150 -0,1950 (-3,97%) Alla chiusura: 05:31PM BST

Affimed N.V.

Gottlieb-Daimler-Straße 2
Mannheim 68165
Germany
49 621 560030
https://www.affimed.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 76

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Andreas Harstrick M.D.	Interim CEO, Chief Medical Officer & Member of Management Board	482,74k	N/D	1961
Dr. Wolfgang Fischer Ph.D.	MD, COO & Member of Management Board	583,58k	N/D	1964
Ms. Denise Mueller	Chief Business Officer & Member of Management Board	522,43k	N/D	1970
Prof. Melvyn Little	Founder & Consultant	N/D	N/D	N/D
Mr. Michael Wolf	Head of Finance & Administration	N/D	N/D	1967
Mr. Alexander Fudukidis	Head of Investor Relations & Director of Investor Relations	N/D	N/D	N/D
Mary Beth Sandin	Vice President of Marketing & Communications	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Governance aziendale

L'ISS Governance QualityScore di Affimed N.V. al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 3; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.